中国血液净化

中国血液净化 ›› 2017, Vol. 16 ›› Issue (07): 442-445.doi: 10.3969/j.issn.1671-4091.2017.07.003

• 综述与讲座 • 上一篇    下一篇

慢性肾脏病患者丙型肝炎感染诊治进展

吴鸿雁1,胡章学1   

  1. 四川大学华西医院肾脏内科
  • 收稿日期:2016-11-21 修回日期:2017-01-14 出版日期:2017-07-12 发布日期:2017-07-14
  • 通讯作者: 胡章学 hzxawy@hotmail.com E-mail:hzxawy@hotmail.com

Advances in the treatment of hepatitis C virus infection in chronic kidney disease patients

  • Received:2016-11-21 Revised:2017-01-14 Online:2017-07-12 Published:2017-07-14

PDF

502

摘要： 丙型肝炎病毒可导致肾脏损伤，增加透析人群全因死亡及心血管死亡率，降低肾移植后移植物存活率，控制慢性肾脏病患者的丙型肝炎感染十分重要。但是，对于透析患者干扰素为基础的抗病毒治疗副作用多，病毒应答较低，干扰素与肾移植后排斥反应及移植物失功密切相关，在血液透析和肾移植人群中使用较少。直接抗病毒药物是一种新问世的抗病毒药物，具有高效、低副作用的特点，将为此类患者提供新的治疗可能。

关键词: 丙型肝炎病毒, 慢性肾脏病, 血液透析, 肾移植, 直接抗病毒药物

Abstract: Hepatitis C virus (HCV) infection can cause renal injury, increase the all-cause and cardiovascular mortality in the dialysis population, and decrease the graft survival among kidney transplant patients. Control of HCV infection is therefore critical to these patients. Interferon-based therapy is rarely used among dialysis and kidney transplant patients due to its frequent side effects, low virological responses, higher rejection and graft failure. The presence of highly efficacious, well-tolerated direct-acting antiviral agents provides an ideal way to cure HCV infection in chronic kidney disease patients.

Key words: Hepatitis C virus, Chronic kidney disease, Hemodialysis, Kidney transplant, Direct-acting antiviral agents